Table 2.
Patient Characteristics at Study Entry for Analyzable Cases (n=82)
| Arm A (n=26) n (%) |
Arm B (n=29) n (%) |
Arm C (n=27) n (%) |
|
|---|---|---|---|
| Age | |||
| Median | 60 | 52 | 53 |
| Range | 27–75 | 27–85 | 25–78 |
| <55 years | 10 (39) | 16 (55) | 14 (52) |
| ≥55 years | 16 (62) | 13 (45) | 13 (48 |
| Gender | |||
| Male | 14 (54) | 11 (38) | 20 (74) |
| Female | 12 (46) | 18 (62) | 7 (26) |
| Race | |||
| White | 22 (85) | 23 (79) | 27 (100) |
| Black | 1 (4) | 4 (14) | 0 (0) |
| Other | 3 (12) | 2 (7) | 0 (0) |
| FAB Classification | |||
| M1 | 8 (31) | 9 (31) | 7 (26) |
| M2 | 2 (8) | 9 (31) | 10 (37) |
| M4 | 6 (23) | 4 (14) | 3 (11) |
| M5 | 0 (0) | 3 (10) | 3 (11) |
| M6 | 2 (8) | 0 (0) | 0 (0) |
| Other+ | 8 (31) | 4 (14) | 4 (15) |
| Immunophenotype | |||
| CD65−, undifferentiated | 9 (29) | 7 (23) | 15 (48) |
| CD11b+ | 6 (32) | 10 (53) | 3 (16) |
| CD 65+, differentiated | 2 (22) | 5 (56) | 2 (22) |
| Megakaryocytic | 5 (56) | 3 (33) | 1 (11) |
| Monocytic (CD14+) | 1 (25) | 1 (25) | 2 (50) |
| Natural killer | 1 (33) | 0 (0) | 2 (67) |
| Erythroid | 1 (100) | 0 (0) | 0 (0) |
| Dendritic cell (CD4+, CD56+) | 0 (0) | 1 (100) | 0 (0) |
| Recurrence Status | |||
| Relapse ≤ 6 months after first CR | 7 (27) | 6 (21) | 6 (22) |
| Relapse > 6–12 months after first CR | 9 (35) | 11 (38) | 11 (41) |
| Refractory | 10 (39) | 10 (35) | 9 (33) |
| Second of greater relapse | 0 (0) | 2 (7) | 1 (4) |
| White Blood Cell count (×109/l) | |||
| Median | 4.9 | 3.3 | 3.4 |
| Range | 0.5–71.6 | 0.5–128.0 | 0.4–113.0 |
| Bone Marrow Blast Cell Count (%) | |||
| Median | 69 (n=25) | 50.0 (n=25) | 53.5 (n=26) |
| Range | 10.0–98.0 | 7.0–94.0 | 12.0–95.0 |